Mina, Roberto http://orcid.org/0000-0002-8144-541X
Falcone, Antonietta Pia
Bringhen, Sara http://orcid.org/0000-0003-4539-6363
Liberati, Anna Marina http://orcid.org/0000-0002-3686-3188
Pescosta, Norbert
Petrucci, Maria Teresa
Ciccone, Giovannino
Capra, Andrea
Patriarca, Francesca
Rota-Scalabrini, Delia
Bonello, Francesca
Musolino, Caterina
Cea, Michele http://orcid.org/0000-0003-3345-0799
Zambello, Renato http://orcid.org/0000-0002-8799-5324
Tacchetti, Paola
Belotti, Angelo http://orcid.org/0000-0002-0617-3127
Cellini, Claudia
Paris, Laura http://orcid.org/0000-0002-8248-2343
Grasso, Mariella
Aquino, Sara
De Paoli, Lorenzo
De Sabbata, Giovanni
Ballanti, Stelvio
Offidani, Massimo
Boccadoro, Mario http://orcid.org/0000-0001-8130-5209
Monaco, Federico http://orcid.org/0000-0002-4630-753X
Corradini, Paolo http://orcid.org/0000-0002-9186-1353
Larocca, Alessandra http://orcid.org/0000-0002-2070-3702
Article History
Received: 1 July 2021
Revised: 18 November 2021
Accepted: 25 November 2021
First Online: 7 December 2021
Competing interests
: RM has received honoraria from Sanofi, Celgene, Takeda, and Janssen; has served on the advisory boards for Sanofi, Takeda, Bristol Myers Squibb, and Janssen; has received consultancy fees from Janssen. SBr has received honoraria from Celgene, Amgen, Oncopeptides, Janssen, and Sanofi; has served on the advisory boards for Takeda, Janssen, GlaxoSmithKline, Sanofi, Bristol Myers Squibb, and Oncopeptides; has received consultancy fees from Janssen, Takeda, Amgen, and Sanofi. AML has received research grants from Takeda, Servier, Roche, Celgene, AbbVie, Incyte, Janssen, Sanofi, Verastem, Novartis, Morphosys, GlaxoSmithKline, Oncopeptides, Karyopharm, Onconova, Archigen, Pfizer, Fibrogen, and Beigene; has received consulting fees from Incyte; has received honoraria from IQVIA, Servier, Celgene, AbbVie, Bristol Myers Squibb, and Janssen; has received travel or meeting support from Takeda, Roche, Janssen, Celgene, Bristol Myers Squibb, AbbVie, Novartis, Sanofi, IQVIA, and Verastem; has served on the advisory boards of Amgen and Servier. MTP has received honoraria from and served on the advisory boards for Celgene, Janssen-Cilag, Bristol Myers Squibb, Takeda, Amgen, Sanofi, and Karyopharm. FP has served on the advisory boards for Celgene, Janssen, Takeda, and Sanofi. MC has received advisory fees from Celgene, Janssen, and Takeda; has received research funding from Celgene. RZ has served on the advisory boards for Celgene, Takeda, Amgen, Janssen, and GlaxoSmithKline. PT has received honoraria from Amgen, Bristol Myers Squibb/Celgene, Janssen, Takeda, AbbVie, Sanofi, GlaxoSmithKline, and Oncopeptides. AB has served on the advisory boards of Janssen, Celgene, Amgen, and GlaxoSmithKline; has received consultancy fees from Takeda. LP has received honoraria from Celgene, Takeda, Amgen, Bristol Myers Squibb, and Janssen; has served on the advisory boards for Celgene, Bristol Myers Squibb, Amgen, and Janssen; has received consultancy fees from Janssen. SBa has received honoraria from and/or served on the scientific advisory boards for Celgene, Janssen, Takeda, Bristol Myers Squibb, Amgen, and Novartis. MO has received honoraria from and served on the advisory boards for Amgen, Bristol Myers Squibb, Celgene, Janssen, and Takeda. MB has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol Myers Squibb, and AbbVie; has served on the advisory boards for Janssen and GlaxoSmithKline; has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol Myers Squibb, and Mundipharma. PC has received honoraria from AbbVie, ADC Therapeutics, Amgen, Celgene, Daiichi Sankyo, Gilead/Kite, GlaxoSmithKline, Incyte, Janssen, Kyowa Kirin, Nerviano Medical Science, Novartis, Roche, Sanofi, and Takeda. AL has received honoraria from Amgen, Bristol Myers Squibb, Celgene, Janssen, and GlaxoSmithKline; has served on the advisory boards for Bristol Myers Squibb, Celgene, Janssen, and Takeda. The remaining authors declare no conflict of interest.